MedTrace Logo

Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma

NCT07088484 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-07-28

No results posted yet for this study

Summary

The purpose of this study is to compare chemotherapy plus immunotherapy with immunochemotherapy combined subsequent locoregional radiotherapy in recurrent nasopharyngeal carcinoma (NPC), in order to confirm the value of immunotherapy and chemotherapy in recurrent NPC patients.

Conditions

  • Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG

ICI-chemotherapy and LIMT

gemcitabine, docetaxel, paclitaxel, cisplatin, platinum, capecitabine, S1; Tislelizumab.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2027-09-01
Completion
2027-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07088484 on ClinicalTrials.gov